Brokerages Set Genomic Health, Inc. (GHDX) Price Target at $31.83

Genomic Health, Inc. (NASDAQ:GHDX) has been given a consensus recommendation of “Hold” by the ten research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $31.83.

GHDX has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies restated a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Canaccord Genuity reduced their price objective on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, August 15th. Finally, Cowen and Company restated a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st.

Genomic Health (NASDAQ:GHDX) traded up 2.29% during trading on Friday, reaching $33.56. The company had a trading volume of 116,399 shares. The stock’s market capitalization is $1.16 billion. Genomic Health has a 1-year low of $26.37 and a 1-year high of $33.97. The firm has a 50-day moving average of $31.67 and a 200-day moving average of $31.66.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The firm had revenue of $85.50 million during the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. Genomic Health’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.18) EPS. On average, analysts anticipate that Genomic Health will post ($0.04) EPS for the current fiscal year.

In other news, insider James J. Vaughn sold 8,000 shares of Genomic Health stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total transaction of $244,720.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $30.22, for a total transaction of $151,100.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,000 shares of company stock valued at $1,022,620. Insiders own 46.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of GHDX. Renaissance Technologies LLC lifted its position in shares of Genomic Health by 27.1% during the 1st quarter. Renaissance Technologies LLC now owns 733,200 shares of the medical research company’s stock valued at $23,088,000 after acquiring an additional 156,500 shares during the period. Vanguard Group Inc. lifted its position in shares of Genomic Health by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock valued at $49,256,000 after acquiring an additional 126,807 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Genomic Health by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 294,048 shares of the medical research company’s stock valued at $9,259,000 after acquiring an additional 81,425 shares during the period. Cowen Prime Services LLC lifted its position in shares of Genomic Health by 324.1% during the 2nd quarter. Cowen Prime Services LLC now owns 88,635 shares of the medical research company’s stock valued at $2,885,000 after acquiring an additional 67,735 shares during the period. Finally, Eagle Asset Management Inc. lifted its position in shares of Genomic Health by 18.4% during the 2nd quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock valued at $12,351,000 after acquiring an additional 58,920 shares during the period. Institutional investors own 88.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Brokerages Set Genomic Health, Inc. (GHDX) Price Target at $31.83” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/brokerages-set-genomic-health-inc-ghdx-price-target-at-31-83.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply